Discontinue if abnormal LFTs persist or worsen clinical signs & symptoms consistent w/ liver disease develop or other manifestations occur (eosinophilia, rash); at 1st appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. W/draw treatment when GI bleeding or ulceration occurs. Avoid use in case of varicella. Increased risk of aseptic meningitis in patients w/ SLE & mixed connective tissue disorders. Exfoliative dermatitis, SJS, TEN; anaphylactic/anaphylactoid reactions. Fluid retention & oedema. Patients suffering from, or w/ previous history of, bronchial asthma; w/ cardiac impairment, those taking diuretics or recovering from major surgery; hepatic porphyria; CHF (NYHA-I), significant risk factors for CV events eg, HTN, hyperlipidaemia, DM, smoking; history of cerebrovascular bleeding, GI ulceration, bleeding or perforation; upper or lower GIT disorders, ulcerative colitis or Crohn's disease, or haematological abnormalities. Monitor renal function in patients at greatest risk of prostaglandin reduction; hepatic function (elevation of liver enzymes) & blood counts in long-term treatment. May reversibly inhibit platelet aggregation. Consider combination therapy w/ protective agents (eg, misoprostol or PPIs) in patients w/ history of ulcer w/ haemorrhage or perforation & in elderly, & those taking concomitant low dose aspirin, or other drugs likely to increase GI risk. Avoid concomitant use w/ other NSAIDs including COX-2 selective inhibitors. Concomitant use w/ systemic corticosteroids, anticoagulants (eg, warfarin), SSRIs or antiplatelet agents eg, aspirin. May affect ability to drive & use machines. Mild to moderate renal & hepatic impairment. Liver dysfunction. May impair female fertility. Not recommended in women attempting to conceive. Increased risk of miscarriage, cardiac malformation or gastroschisis in early pregnancy. Not to be given during 1st & 2nd trimester of pregnancy. Avoid use in lactation. Not recommended in childn. Elderly.
Sign Out
